Cambridge Healthtech Institute’s 4th Annual
AI/ML-Enabled Drug Discovery
Part 1: Design and Optimization of Novel Drugs and Modalities
September 23-24, 2025
Part 2: Discovering and Validating New Targets, Pathways, and Drug Responses
September 24-25, 2025
Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, predictive modeling, algorithms, and data analysis for identifying novel drug targets, designing new drug candidates, optimizing leads, and ADMET properties, drug repurposing and other diverse applications. Relevant case studies and research findings will show where and how AI/ML can be successfully applied, integrated, and implemented in drug discovery. It will bring together chemists, biologists, pharmacologists, data scientists, and bioinformaticians to talk about what is being done and what can be made possible, while understanding the underlying caveats of AI-enabled decision-making.
Coverage will include, but is not limited to:
- AI for accelerating target identification and validation
- AI-enabled drug design and hit-to-lead prioritization
- Optimum use of AI-based predictive modeling and virtual screening
- ML approaches to predict binding and drug-like properties
- AI/ML for predicting ADME and safety profiles
- AI/ML for understanding cellular pathways and interactions
- AI/ML for predicting drug response and adverse events
- AI-driven drug repurposing
- Understanding agentic AI and other emerging tools
- Use of small and large language models for drug discovery
The deadline for priority consideration is March 7, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: